Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 71-80 of 639 results
The Journal of Spinal Cord Medicine, 2022 • January 1, 2022
This clinical review assessed the use of Botulinum Toxin type A (BTX-A) for treating neuropathic pain in patients with spinal cord injuries, examining studies up to May 2020. The review found limited,...
KEY FINDING: There's limited research specifically on using BTX-A to treat neuropathic pain related to spinal cord injury, despite broader studies on other patient populations.
The Journal of Spinal Cord Medicine, 2022 • January 1, 2022
The study aimed to investigate the synergistic neuroprotective effects of combined HBO and MP treatment on SCI in rats. The experimental design included sham, SCI, MP, HBO, and HBO + MP groups. The re...
KEY FINDING: Combination therapy with HBO and MP significantly decreased MDA (malondialdehyde) levels, indicating reduced lipid peroxidation, compared to other treatment groups.
Cellular and Molecular Neurobiology, 2022 • April 22, 2021
This review provides an overview of miR-124, its roles in CNS development, and summarizes recent data of its role in neuroinflammation, ischemic stroke, SCI, NDDs, GBM, MS, and the methods for the del...
KEY FINDING: miR-124 acts as one of the key miRNAs regulating neuroinflammation in various CNS pathologies, which may shed light on novel therapies targeting miR-124 for treating CNS insults.
Cellular and Molecular Neurobiology, 2023 • June 1, 2022
This meta-analysis examined the therapeutic potential of miRNA therapy for acute spinal cord injury (SCI) in rodent models. The study synthesized data from multiple publications to evaluate the impact...
KEY FINDING: Rats receiving miRNA therapy showed significant recovery in SCI models based on BBB scores.
Neural Regeneration Research, 2022 • December 1, 2022
The study aimed to elucidate the underlying mechanism by which HBO alleviates SCI through genome-wide transcriptional profiling. The findings revealed the genome-wide transcriptional profile of the in...
KEY FINDING: HBO treatment significantly alleviated pathological changes of damaged spinal cord and improved motor function of mice after SCI.
Drug Delivery, 2022 • January 1, 2022
This study successfully synthesized chitosan-modified hollow manganese dioxide nanoparticles (CM) to deliver resveratrol (Res) for spinal cord injury (SCI) treatment. In vitro and in vivo experiments ...
KEY FINDING: Chitosan modification enables HM to cross the blood–spinal cord barrier (BSCB) and deliver Res to the injury site.
CNS Neuroscience & Therapeutics, 2022 • July 15, 2022
This study investigates the effect of apigenin on fibrous scar formation after spinal cord injury (SCI) in mice. Apigenin, a natural flavonoid, was administered to mice with SCI, and its effects on sc...
KEY FINDING: Apigenin inhibits fibrous scar formation in the mouse spinal cord after SCI, as evidenced by reduced expression of fibroblast-related parameters and decreased myofibroblast activation.
J. Med. Chem., 2022 • August 10, 2022
This study introduces UCM-14216, a novel and potent LPA2 antagonist, demonstrating its potential to ameliorate spinal cord injury in mice. UCM-14216 exhibits a favorable pharmacokinetic profile, reach...
KEY FINDING: UCM-14216 is a potent and selective LPA2 receptor antagonist, showing high efficacy in blocking the receptor's activity.
Pain, 2023 • May 1, 2023
This study investigated the role of α6-containing GABAA receptors in physiological conditions and neuropathic pain using rats and mice. The study found that α6-containing GABAA receptor blockade or kn...
KEY FINDING: α6-containing GABAA receptor blockade or knockdown induces hypersensitivity and spontaneous pain in naïve female rats.
Neural Plasticity, 2022 • August 29, 2022
This review explores the relationship between TSPO and chronic pain, highlighting its vital role in alleviating the initiation and maintenance of various types of chronic pain. TSPO acts as a negative...
KEY FINDING: TSPO is upregulated with microglial activation during neuroinflammation, serving as a marker and predictor of chronic pain.